Veterinary Neuromodulation Market - By Technology: Spinal Cord Stimulation (SCS), Transcutaneous Vagus Nerve Stimulation (tVNS), Deep Brain Stimulation (DBS); By Animal Type: Companion Animals, Livestock; By Region: North America, Europe, Asia-Pacific Latin America and Middle East and Africa
Veterinary Neuromodulation Market is projected to grow from USD 680 million in 2024 to USD 2.1 billion by 2031, reflecting a 20.5% CAGR, driven by opioid bans and the demand for non-pharmacological pain management.
Market Segmentation
1.1 By Technology
1.2 By Animal Type
1.3 By Geography
2. Key Growth Drivers
2.1 Regulatory Shifts
2.2 Clinical Advancements
2.3 Economic Benefits
|
Metric |
Neuromodulation |
Traditional Drugs |
|
Cost/Dog (5 Years) |
USD 5,200 |
USD 12,000 |
|
Livestock ROI |
20% premium for "stress-free" pork |
8% with sedatives |
3. Competitive Landscape
|
Company |
Breakthrough |
Market Impact |
|
Nexstim |
CaniStim® (SCS for dogs) |
USD 120M revenue (2023) |
|
VetNeuro |
PulseVet® (tVNS for livestock) |
50K devices deployed |
|
Medtronic |
AdaptivStim® (AI-driven SCS) |
30% lower seizures in trials |
4. Future Outlook (2025–2030)
Need help?
Chat with our team in a minute.